These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11870441)

  • 61. Scintigraphic evaluation of Tc-99m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease.
    Lorberboym M; Vallabhajosula S; Lipszyc H; Pastores G
    Clin Genet; 1997 Jul; 52(1):7-11. PubMed ID: 9272706
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease.
    Erba PA; Minichilli F; Giona F; Linari S; Dambrosia J; Pierini A; Filocamo M; Di Rocco M; Buffoni F; Brady RO; Mariani G
    J Nucl Med; 2013 Oct; 54(10):1717-24. PubMed ID: 23990684
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Insulin-like growth factors in childhood-onset Gaucher disease.
    Rite S; Baldellou A; Giraldo P; Labarta JI; Giralt M; Rubio-Felix D; Guallar A; Perez-Calvo JI; Mayayo E; Ferrandez A; Pocovi M
    Pediatr Res; 2002 Jul; 52(1):109-12. PubMed ID: 12084856
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pediatric Gaucher experience in South Marmara region of Turkey.
    Erdemır G; Özkan T; Özgür T; Yazici Z; Özdemır Ö
    Turk J Gastroenterol; 2011 Oct; 22(5):500-4. PubMed ID: 22234757
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
    Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of high density lipoprotein in Type 1 Gaucher disease.
    Watad S; Abu-Saleh N; Yousif A; Agbaria A; Rosenbaum H
    Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Normal sonographic liver and spleen dimensions in a central European pediatric population.
    Waelti S; Fischer T; Wildermuth S; Leschka S; Dietrich T; Guesewell S; Mueller P; Ditchfield M; Markart S
    BMC Pediatr; 2021 Jun; 21(1):276. PubMed ID: 34116649
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
    Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
    Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.
    Barton NW; Furbish FS; Murray GJ; Garfield M; Brady RO
    Proc Natl Acad Sci U S A; 1990 Mar; 87(5):1913-6. PubMed ID: 2308952
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
    Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
    Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of enzyme replacement therapy on gammopathies in Gaucher disease.
    Brautbar A; Elstein D; Pines G; Abrahamov A; Zimran A
    Blood Cells Mol Dis; 2004; 32(1):214-7. PubMed ID: 14757437
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
    Chan LL; Lin HP
    Med J Malaysia; 2002 Sep; 57(3):348-52. PubMed ID: 12440275
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Analysis of the densitometric method of hand bone radiograms and assessment of early changes of bone structure in the children with Gaucher's disease on enzyme replacement therapy (ERT)].
    Łyson-Wojciechowska G; Skawiński W; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2007; 13(4):218-223. PubMed ID: 18183671
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
    Zimran A; Wajnrajch M; Hernandez B; Pastores GM
    Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Management of Gaucher disease: enzyme replacement therapy.
    Zimran A; Elstein D
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():82-7. PubMed ID: 25345089
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P; Drugan C; Cret V; Al-Kzouz C; Denes C; Coldea C; Zimmermann A
    J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease.
    Goker-Alpan O; Wiggs EA; Eblan MJ; Benko W; Ziegler SG; Sidransky E; Schiffmann R
    J Pediatr; 2008 Jul; 153(1):89-94. PubMed ID: 18571543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.